Ravi Majeti MD, PhD is the RZ Cao Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >100 peer-reviewed articles. Ongoing work in the lab covers a diverse range of topics and includes studies of stem cells, pre-leukemia, epigenetics, genomics, genome editing, cancer systems biology, synthetic lethality, small molecule drug development, immunotherapy, CAR-T cells, cancer vaccination, and RNA-based gene therapy. Diseases investigated include pre-leukemic/clonal hematopoiesis, adult and pediatric AML, MDS, and ALL. He is a recipient of the Burroughs Welcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award. Dr. Majeti is a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and the American Association for Cancer Research (AACR) Task Force on Hematologic Malignancies. He also serves of the editorial boards of Blood, Cell Stem Cell, and Cancer Discovery.